Ready for a comeback of natural products in oncology
- 1 May 2009
- journal article
- editorial
- Published by Elsevier in Biochemical Pharmacology
- Vol. 77 (9) , 1447-1457
- https://doi.org/10.1016/j.bcp.2008.12.013
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Marine pharmacology in 2005–2006: Antitumour and cytotoxic compoundsEuropean Journal Of Cancer, 2008
- Advances in and applications of proteasome inhibitorsCurrent Opinion in Chemical Biology, 2008
- Biosynthetic origin of natural products isolated from marine microorganism–invertebrate assemblagesProceedings of the National Academy of Sciences, 2008
- Proteasome Inhibitors in Cancer Therapy: Lessons from the First DecadeClinical Cancer Research, 2008
- The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell deathBlood, 2008
- Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myelomaBlood, 2008
- Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomaBlood, 2007
- Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743Proceedings of the National Academy of Sciences, 2007
- A high throughput drug screen based on fluorescence resonance energy transfer (FRET) for anticancer activity of compounds from herbal medicineBritish Journal of Pharmacology, 2007
- Manipulation of Alternative Splicing by a Newly Developed Inhibitor of ClksJournal of Biological Chemistry, 2004